Relugolix and Aripiprazole Lauroxil: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Aripiprazole Lauroxil
Relugolix
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed two medicines that can each affect your heart's rhythm. Aristada (aripiprazole lauroxil) is a long-acting antipsychotic, and Orgovyx (relugolix) is used to lower testosterone in prostate cancer. Both can gently stretch out a part of your heartbeat called the QT interval. Taken together, that effect can add up and, rarely, lead to an irregular heartbeat.
The good news is that this concern is mostly theoretical, and your care team can manage it easily. They may check an ECG and your blood minerals (like potassium and magnesium) now and then. Keep taking both as prescribed, and let your doctor or pharmacist know if you feel fainting, dizziness, or a fluttering heartbeat.
Additive QT prolongation (pharmacodynamic, not metabolic). Both agents independently prolong the QT interval: aripiprazole via its intrinsic effect, and relugolix through androgen-deprivation-associated QT prolongation. Combined use raises the theoretical risk of QTc prolongation and torsades de pointes.
- Direction: additive QT effect; no CYP prodrug mechanism involved
- Evidence: theoretical; severity: major; onset unspecified
- Management: avoid concomitant use when feasible; weigh ADT benefit against risk, especially with congenital long QT, CHF, or electrolyte disturbances. If used together, correct and maintain normal K+/Mg2+, avoid agents causing electrolyte loss, and consider periodic ECG and electrolyte monitoring.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
When relugolix is given alongside medications that prolong the QT interval, the effects on the QT interval are additive. The androgen deprivation produced by GnRH agonists or antagonists can itself lengthen the QT interval. In patients who have congenital long QT syndrome, congestive heart failure, or recurrent electrolyte disturbances, as well as those receiving drugs recognized to prolong the QT interval, weigh whether the benefits of androgen deprivation therapy such as relugolix outweigh the possible risks1. Where feasible, do not use relugolix together with agents that prolong the QT interval. When coadministration cannot be avoided, refrain from using drugs that produce electrolyte abnormalities (that is, hypokalemia or hypomagnesemia)2, correct any electrolyte abnormalities, and consider periodic monitoring of ECGs and electrolytes1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Both medicines can lengthen the QT interval, so your care team will manage this thoughtfully. Typically they:
- Decide whether the benefit of relugolix outweighs the risk, especially if you have a heart-rhythm condition, heart failure, or frequent electrolyte problems.
- Keep potassium and magnesium in normal range, correcting any imbalance.
- Consider periodic ECGs and blood electrolyte checks.
What you can do: keep taking both exactly as prescribed, and do not stop either on your own. Ask your pharmacist or doctor before adding new medicines, and report any fainting, dizziness, palpitations, or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) A study examined male patients undergoing androgen deprivation therapy (ADT) using individual case safety reports from VigiBase, the international pharmacovigilance database, and found 184 cases of acquired long-QT syndrome (aLQTS) and/or torsades de pointes (TdP; 11% of cases fatal), along with 99 cases of sudden death linked to ADT. The majority of aLQTS/TdP cases (62%) and sudden death cases (88%) tied to ADT arose without concurrent use of other agents known to raise TdP risk; nonetheless, use of 1 drug and of 2 or more drugs carrying conditional, possible, or known TdP risk was documented in a portion of aLQTS/TdP events (23% or 43%) and sudden death events (18% and 22%). The agents classified as ADTs included abiraterone, gonadotropin-releasing hormone agonists and antagonists, nonsteroidal androgen receptor inhibitors used for prostate cancer, and 5-alpha-reductase inhibitors used for androgenic alopecia and prostatism. Among the 10 ADTs assessed, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, namely leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The median patient age was roughly 76 years, and the median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients were primarily receiving ADT for prostate cancer, with some treated for prostatism and androgenic alopecia. Most patients received ADT as monotherapy (83%); 17% were on ADT combination therapy 3.
Common questions
Can I take Relugolix and Aripiprazole Lauroxil together?
Both drugs can add to QT prolongation, so your care team may monitor your ECG and electrolytes; keep taking both as prescribed and report any fainting or palpitations. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Relugolix and Aripiprazole Lauroxil interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Relugolix and Aripiprazole Lauroxil interaction managed?
Both medicines can lengthen the QT interval, so your care team will manage this thoughtfully. Typically they: Decide whether the benefit of relugolix outweighs the risk, especially if you have a heart-rhythm condition, heart failure, or frequent electrolyte problems. Keep potassium and magnesium in normal range, correcting any imbalance. Consider periodic ECGs and blood electrolyte checks. What yo… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Relugolix or Aripiprazole Lauroxil need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Keep reading about Aripiprazole Lauroxil
Keep reading about Relugolix
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist